Q-omics provides the consensus-scored HBD profile across patient tissues and cancer cell-line models. HBD expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HBD is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, HBD protein abundance shows 17,028 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight HNSC, KICH, and CCRCC as cancer lineages where HBD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HBD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HBD survival associations across molecular data types. HBD RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HBD RNA expression–survival associations across cancer types. High HBD expression shows unfavorable associations in CHOL, but favorable associations in HNSC, SKCM, KIRC, COAD and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for HBD RNA expression.
This table summarizes HBD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in LUSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for HBD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HBD shows lower tumor expression in KICH, LUSC, LUAD, THCA, UCEC and BRCA. The KICH box plot shows higher HBD RNA expression in normal versus tumor tissue (log2 FC = −1.205, t-test p < 0.001).
This table shows molecular features associated with HBD in patient tissues and cancer cell lines. In patient samples, HBD shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HBD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
